MALVERN, Pa. and ST. SAVOUR, Jersey, June 03, 2024 (GLOBE NEWSWIRE) — BioPharmaSpec (“BioPharmaSpec”), a leading global contract research organization (CRO) specializing in biopharmaceutical discovery and preclinical characterization, has made significant new investments in instrumentation, including a top-of-the-line mass spectrometer, to support its clients’ product development objectives.
June 1, 2024 Biopharmaspec recently announced a new Mass spectrometry Measuring instruments, including: Waters Select Series CYCLIC IMS High Resolution LC-MS/MS with ECD, SCIEX ZenoTOF 7600 LC-MS/MS (with EAD), Waters Xevo TQ Absolute and Waters Xevo G3 LC-MS/MS Q-TOF.
To further support customers in providing first class characterization services, BioPharmaSpec has expanded its overall analytical instrumentation portfolio. Bio-Techne (Protein Simple) Maurice Flex icIEF, CE-SDS, cIEF instrument, two Shimadzu PPSQ-53A gas phase sequencers, and a Wyatt DAWN Ambient 18-angle multi-angle light scattering with integrated DLS and Optilab dRI detectors.
The instruments, currently installed and certified in BioPharmaSpec’s laboratories around the world, will further enhance BioPharmaSpec’s already excellent mass spectrometry, chromatography and spectroscopy service offerings.
About BioPharmaSpec
BioPharmaSpec is a CRO specializing in the structural characterization and physicochemical analysis of recombinant biopharmaceuticals, including a range of product types, including biosimilars and biobetters, monoclonal antibodies, antibody drug conjugates (ADCs), gene therapy products (e.g. AAV-based therapeutics), peptides and oligonucleotides, with a focus on discovery, early-stage and preclinical phases.
contact:
Lindsay McGowan, Director of Business Development, BioPharmaSpec
Email: l.mcgowan@biopharmaspec.com
For more information, please visit https://biopharmaspec.com/.
